TSPAN17: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: TSPAN17

NCBI ID: G26262

TSPAN17

TSPAN17: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Introduction

Neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's diseases, are characterized by the progressive loss of brain cells and their respective neurotransmitters, leading to the decline in cognitive and motor functions. Currently, there is no cure for these debilitating conditions, and numerous pharmaceuticals are available only to alleviate symptoms. Therefore, identifying potential drug targets and biomarkers for these diseases remains a major focus in research. TSPAN17, a gene expressed in the brain, has emerged as a promising candidate for these disorders. This article will discuss the potential implications of TSPAN17 as a drug target and biomarker in neurodegenerative diseases.

The TSPAN17 gene

TSPAN17 (TSPAN17), which encodes a protein known as TSPAN-17, is a non-coding RNA molecule that is expressed in various tissues, including the brain. The protein encoded by TSPAN17 is composed of 214 amino acids and has a calculated molecular mass of 21.4 kDa. It is localized to the brain and contains a putative transmembrane domain, a known structural feature that is conserved in various proteins involved in cell signaling pathways.

Function and localization

TSPAN17 is involved in various cellular processes, including cell signaling, neurotransmitter release, and synaptic plasticity. It is a critical regulator of the cAMP/Ca2+ signaling pathway, which is involved in memory and learning processes. TSPAN17 has been shown to localize to the endoplasmic reticulum (ER) and to play a role in regulating the trafficking of proteins to the ER.

In addition to its role in cell signaling, TSPAN17 is also implicated in the development and progression of neurodegenerative diseases. For example, TSPAN17 has been shown to be overexpressed in various neurodegenerative models, including dopamine-dependent motor neuron disease, amyloid neurodegeneration, and neurofibrillary tangles in Alzheimer's disease.

Drug targeting and biomarker potential

TSPAN17 has the potential to serve as a drug target for neurodegenerative diseases due to its involvement in various cellular processes that are affected in these conditions. Several studies have suggested that TSPAN17 could be a target for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

First, TSPAN17 has been shown to be involved in the regulation of the production of neurotransmitters, such as dopamine and serotonin, which are involved in various cognitive functions. Overexpression of TSPAN17 has been shown to impair neurotransmitter release and to cause neurodegeneration in various cell models, suggesting that it may play a negative role in the regulation of neurotransmitter homeostasis.

Second, TSPAN17 has been implicated in the development and progression of neurodegenerative diseases due to its association with various proteins involved in these conditions, including tau, a protein that is involved in the regulation of microtubules, and beta-secretase. Overexpression of TSPAN17 has been shown to increase the levels of tau and beta-secretase in various cell models, leading to the aggregation of these proteins and the development of neurodegeneration.

Finally, TSPAN17 has been shown to be involved in the regulation of synaptic plasticity, which is the ability of the nervous system to change and adapt over time. Overexpression of TSPAN17 has been shown to impair synaptic plasticity in various cell models, suggesting that it may play a negative role in the regulation of

Protein Name: Tetraspanin 17

Functions: Regulates ADAM10 maturation

The "TSPAN17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSPAN17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets